Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13501682 | 1.00 | SLC5A2 (0.73) | SLC5A2 | |
| SCHEMBL8984696 | 1.00 | SLC5A2 (0.73) | SLC5A2 | |
| SCHEMBL15682799 | 1.00 | SLC5A2 (0.73) | SLC5A2 | |
| SCHEMBL15297958 | 1.00 | SLC5A2 (0.73) | SLC5A2 | |
| SCHEMBL6303449 | 1.00 | SLC5A2 (0.73) | SLC5A2 | |
| SCHEMBL14949090 | 1.00 | SLC5A2 (0.73) | SLC5A2 | |
| SCHEMBL8351368 | 1.00 | SLC5A2 (0.73) | SLC5A2 | |
| SCHEMBL20529512 | 0.98 | SLC5A2 (0.71) | SLC5A2 | |
| SCHEMBL4139162 | 0.98 | SLC5A2 (0.71) | SLC5A2 | |
| SCHEMBL15822614 | 0.92 | SLC5A2 (0.63) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11817195-B2 | Methods for lowering blood sugar with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition | ASTRAZENECA UK LIMITED (GB) | 2023-11-14 | — | — | US | disclosed |
| EP-2252289-B1 | COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-10294259-B2 | Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2019-05-21 | — | — | US | disclosed |
| EP-3246324-A2 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USES THEREOF | Tianjin Institute Of Pharmaceutical Research (CN) | 2017-11-22 | — | — | EP | disclosed |
| EP-2933250-B1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | TIANJIN INST OF PHARMACEUTICAL RES (CN) | 2017-08-09 | — | — | EP | disclosed |
| EP-2776449-B1 | PROCESS FOR THE PREPARATION OF BETA-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN LTD (TW) | 2017-08-02 | — | — | EP | disclosed |
| EP-2776449-B1 | PROCESS FOR THE PREPARATION OF BETA-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN LTD (TW) | 2017-08-02 | — | — | EP | disclosed |
| US-20170057989-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2017-03-02 | — | — | US | disclosed |
| US-20170057989-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2017-03-02 | — | — | US | disclosed |
| US-9505734-B2 | Phenyl C-glucoside derivative containing deoxyglucose structure, preparation method and use thereof | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2016-11-29 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20080234367-A1 | Sodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080119422-A1 | Indole Derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7375213-B2 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375213-B2 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example dapagliflozin | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-20070060545-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| US-7169761-B2 | Azulene derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885 |
| US-20070238866-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885 |
| US-20070060545-A1 | Novel compounds | CYP1B1, CYP2B6, CYP4B1 | SLC5A2 549/4885 |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885 |
| US-11817195-B2 | Methods for lowering blood sugar with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885 |
| US-10294259-B2 | Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof | GCG, SLC5A1, DPP7 | SLC5A2 6/4885 |
| US-20170057989-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | GCG, SLC5A1, DPP7 | SLC5A2 6/4885 |
| US-20080119422-A1 | Indole Derivatives | IDO1, TPH1, NAT1 | SLC5A2 319/4885 |
| US-20080234367-A1 | Sodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.